Global neglected tropical diseases drugs and vaccines market comprise diseases that affect largely developing countries but due to increased international migration, these diseases are now a concern in developed nations. The London Declaration, signed in 2012, aimed to bring in focus neglected tropical diseases (NTDs) to increase diagnostic and treatment access for all as well as lower incidence with the collaborative support of funding bodies and pharmaceutical companies.
In the neglected tropical diseases drugs and vaccines market, funding organizations as well as non-profit drug research and development organizations, including Drugs for Neglected Diseases initiative (DNDI) and Global Alliance for Vaccines and Immunization (GAVI), form the driving force enabling new drug development and better treatment access. Kinetoplastid diseases including Chagas and Leishmaniasis present a growing opportunity with recent regulatory approvals for new drugs and expected vaccine launches over the forecast period. For instance, with funding from Bill and Melinda Gates Foundation, DNDI has driven development of fexinidazole for Chagas disease, an all-oral treatment, which recently gained positive recommendation from the European Medicines Agency.
Diverse catalysts driving the growth of the neglected tropical diseases drugs and vaccines market include drug-resistant malaria and leishmaniasis cases and involvement of funding organizations subsidizing treatment costs in developing nations. Participating funding organizations support disease markets that are significant largely in low-income endemic countries, which are mostly eligible for support from GAVI and Global Drug Facility (GDF). New product approvals such as the launch of the vaccine, Mosquirix for malaria will boost revenue growth in this market.
The pipeline for emerging tropical diseases holds a handful of therapies and vaccines in the late development stages. Novel therapies under phase III clinical development include drugs for malaria with a focus on shorter regimens to increase patient compliance, while the Zika virus and Dengue await their first drug treatments. Among vaccines, Takeda’s dengue vaccine is set to pose strong competition for Dengvaxia beginning 2020. In contrast, vaccines for the Zika virus in phase II/III are expected to enter the market later over the forecast period. The use of these new vaccines in endemic regions to control outbreaks and by outbound travelers in developed regions will contribute to market growth.
Players in this space engage in collaborations with non-profit research and development organizations to fast track development of new therapies and vaccines. One of the prominent partnerships includes Sanofi-DNDI collaboration that is targeting new treatment development for multiple tropical infections. Merck, GSK, and Takeda are some of the other participants in Neglected tropical diseases drugs and vaccines market.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.
"The quality of research they have done for us has been excellent..."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.